Suppr超能文献

平均心脏剂量不能替代左前降支冠状动脉剂量预测肺癌放疗后主要心脏不良事件风险。

Mean Heart Dose Is an Inadequate Surrogate for Left Anterior Descending Coronary Artery Dose and the Risk of Major Adverse Cardiac Events in Lung Cancer Radiation Therapy.

机构信息

Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California; Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1473-1479. doi: 10.1016/j.ijrobp.2021.03.005. Epub 2021 Mar 10.

Abstract

PURPOSE

Mean heart dose (MHD) over 10 Gy and left anterior descending (LAD) coronary artery volume (V) receiving 15 Gy (V15Gy) greater than 10% can significantly increase the risk of major adverse cardiac events (MACE) in patients with non-small cell lung cancer (NSCLC). We sought to characterize the discordance between MHD and LAD dose and the association of this classification on the risk of MACE after radiation therapy.

METHODS AND MATERIALS

The coefficient of determination for MHD and LAD V15Gy was calculated in this retrospective analysis of 701 patients with locally advanced NSCLC treated with radiation therapy. Four groups were defined on the basis of high or low MHD (≥10 Gy vs <10 Gy) and LAD V15Gy (≥10% vs <10%). MACE (unstable angina, heart failure, myocardial infarction, coronary revascularization, and cardiac death) cumulative incidence was estimated, and Fine and Gray regressions were performed.

RESULTS

The proportion of variance in LAD V15Gy predictable from MHD was only 54.5% (R = 0.545). There was discordance (where MHD was high [≥10 Gy] and LAD low [V15Gy < 10%], or vice versa) in 23.1% of patients (n = 162). Two-year MACE estimates were 4.2% (MHD/LAD), 7.6% (MHD/LAD), 1.8% (MHD/LAD), and 13.0% (MHD/LAD). Adjusting for pre-existing coronary heart disease and other prognostic factors, MHD/LAD (subdistribution hazard ratio [SHR], 0.34; 95% CI, 0.13-0.93; P = .036) and MHD/LAD (SHR, 0.24; 95% CI, 0.10-0.53; P < .001) were associated with a significantly reduced risk of MACE.

CONCLUSIONS

MHD is insufficient to predict LAD V15Gy with confidence. When MHD and LAD V15Gy dose exposure is discordant, isolated low LAD V15Gy significantly reduces the risk of MACE in patients with locally advanced NSCLC after radiation therapy, suggesting that the validity of whole heart metrics for optimally predicting cardiac events should be reassessed.

摘要

目的

对于非小细胞肺癌(NSCLC)患者,10 Gy 以上的平均心脏剂量(MHD)和左前降支(LAD)冠状动脉体积(V)接受 15 Gy(V15Gy)大于 10%,会显著增加主要不良心脏事件(MACE)的风险。我们试图描述 MHD 和 LAD 剂量之间的差异,并探讨这种分类与放疗后 MACE 风险之间的关系。

方法与材料

我们对 701 例局部晚期 NSCLC 患者进行了回顾性分析,这些患者接受了放射治疗。根据 MHD(≥10 Gy 与<10 Gy)和 LAD V15Gy(≥10%与<10%)的高低,将患者分为四组。估计 MACE(不稳定型心绞痛、心力衰竭、心肌梗死、冠状动脉血运重建和心脏死亡)的累积发生率,并进行 Fine 和 Gray 回归分析。

结果

LAD V15Gy 可由 MHD 预测的方差比例仅为 54.5%(R=0.545)。在 23.1%的患者中(n=162)存在差异(MHD 高[≥10 Gy]和 LAD 低[V15Gy < 10%],或反之亦然)。两年 MACE 估计值分别为 4.2%(MHD/LAD)、7.6%(MHD/LAD)、1.8%(MHD/LAD)和 13.0%(MHD/LAD)。调整预先存在的冠心病和其他预后因素后,MHD/LAD(亚分布风险比 [SHR],0.34;95%CI,0.13-0.93;P=0.036)和 MHD/LAD(SHR,0.24;95%CI,0.10-0.53;P<0.001)与 MACE 的风险显著降低相关。

结论

MHD 不能可靠地预测 LAD V15Gy。当 MHD 和 LAD V15Gy 剂量暴露存在差异时,孤立的低 LAD V15Gy 可显著降低局部晚期 NSCLC 患者放疗后的 MACE 风险,提示需要重新评估全心脏指标对心脏事件的最佳预测效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验